Targeting METTL3 or IGF2BP2 may represent a promising therapeutic strategy, and the analysis of METTL3 and IGF2BP2 expression could be a potential signature for predicting the sensitivity of clinical radiotherapy in HCC. Here, METTL3 is linked to hepatocellular carcinoma.